Nivolumab Plus Cabozantinib vs Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
ESMO Open
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial
ESMO Open 2024 Apr 19;9(5)102994, T Powles, M Burotto, B Escudier, AB Apolo, MT Bourlon, AY Shah, C Suárez, C Porta, CH Barrios, M Richardet, H Gurney, ER Kessler, Y Tomita, J Bedke, S George, C Scheffold, P Wang, V Fedorov, RJ Motzer, TK ChoueiriFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.